This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Medical Products' Aug 5 Earnings Roster: BDX, RMD & More
by Trina Mukherjee
Let's see how Medical Product companies' stocks like BDX, RMD, CAH, ABMD and XRAY are poised ahead of their earnings releases.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment is expected to have driven up Q3 sales.
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Teleflex (TFX) to Your Portfolio
by Zacks Equity Research
Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Q2 Earnings Scorecard & Analyst Reports for Microsoft, AbbVie & Enbridge
by Sheraz Mian
We have provided a real-time scorecard of the Q2 earnings season, in addition to featuring Microsoft (MSFT), AbbVie (ABBV), Enbridge (ENB) and other stocks.
BD's (BDX) Digital Marketplace Set to Improve User Experience
by Zacks Equity Research
BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
by Trina Mukherjee
Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
BD's (BDX) PeritX System Gets FDA's Expanded 510(k) Clearance
by Zacks Equity Research
BD's (BDX) receipt of the expanded FDA indication for its PeritX System is expected to lessen the number of hospital trips a patient takes for fluid removal.
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch
by Trina Mukherjee
Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.
BD's (BDX) Rapid COVID-19 Test for US Olympic Trial Swimmers
by Zacks Equity Research
BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.
BD's (BDX) Milestone Pandemic Orders to Support Vaccinations
by Zacks Equity Research
BD (BDX) receives 2 billion pandemic orders for needles and syringes to support global COVID-19 vaccination efforts.
BD (BDX) Solidifies Foothold in Healthcare Cybersecurity
by Zacks Equity Research
BD's (BDX) authorization as a CNA is expected to allow it to provide customers with timely information about vulnerabilities in BD products available globally.
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
by Zacks Equity Research
BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.
Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.
BD's (BDX) First Self-Collection HPV Screening Assay Gets CE Mark
by Zacks Equity Research
BD's (BDX) industry-first CE marked self-collection claim for HPV screening enables greater access to testing for women.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
National Vision (EYE) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) transitions of five additional Walmart Vision Centers in 2020, which have become operative of late, are expected to post positive Q1 results.
GoodRx (GDRX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
GoodRx' (GDRX) manufacturer solutions offerings continue to grow at a strong rate, registering record bookings over the past months.
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4.93% and 1.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Becton, Dickinson (BDX)
by Zacks Equity Research
Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in Pharmaceutical segment.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect weak segmental performance.